Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India

Journal of the International Association of Providers of AIDS Care

Volumn 12, Issue 1, 2013, Pages 28-31

  Kumarasamy, N ^a   Venkatesh, Kartik K ^b   Vignesh, R ^a   Devaleenal, B ^a   Poongulali, S ^a   Yepthomi, Tokuga ^a   Flanigan, Timothy P ^b   Benson, Constance ^c   Mayer, Kenneth H ^b  

^a YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^b MIRIAM HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HAART; HIV AIDS; India; Iris; Tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEMOGLOBIN; NEVIRAPINE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INDIA; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPUTUM CULTURE; THORAX RADIOGRAPHY; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INDIA; MALE; TUBERCULOSIS;

EID: 84877909289     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/1545109712457711     Document Type: Article

References (10)

1. French M, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18(12):1615-1627.
2. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis. 2004;39(11):1709-1712.
3. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther. 2005;10(3): 417-422.
4. Kumarasamy N, Chagututu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV/tuberculsos-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr. 2004;37(5): 1574-1576.
5. Shelburne S, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4): 399-406.
6. Murdoch D, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2008;22(5): 601-610.
7. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and anti-retroviral therapy. J Infect. 2006;53(6):357-363.
8. Lawn S, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007; 21(3):335-341.
9. Jevtović D, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2005;6(2):140-143.
10. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006;42(11):1639-1646.